Bacil Pharma Approves ₹50 Cr Rights Issue, Capital Increase

Bacil Pharma Ltd's Board of Directors has approved a proposal to raise up to ₹50 crore through a Rights Issue of equity shares. The board also approved an increase in the authorized share capital by ₹45 crore to ₹65 crore, subject to shareholder approval. Intermediaries for the Rights Issue, including Purva Sharegistry (India) Private Limited as Registrar and Axis Bank as Banker, were appointed. The board accepted the resignations of Independent Directors Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya. A Rights Issue Committee was formed, and Ms. Chaitali Kalpataru Shah and the Company Secretary were authorized to execute necessary documents for the Rights Issue. The trading window remains closed until 48 hours after the board meeting outcome.